Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024

SELL
$12.63 - $24.47 $8.7 Million - $16.9 Million
-689,000 Reduced 86.13%
111,000 $2.62 Million
Q3 2023

Nov 14, 2023

BUY
$10.86 - $17.62 $1.43 Million - $2.31 Million
131,298 Added 19.63%
800,000 $11.9 Million
Q2 2023

Aug 14, 2023

BUY
$7.47 - $10.95 $363,803 - $533,286
48,702 Added 7.86%
668,702 $7.32 Million
Q1 2023

May 15, 2023

SELL
$5.88 - $9.59 $2.38 Million - $3.88 Million
-405,000 Reduced 39.51%
620,000 $5.41 Million
Q4 2022

Feb 14, 2023

SELL
$3.22 - $6.27 $2.33 Million - $4.55 Million
-725,000 Reduced 41.43%
1,025,000 $6.43 Million
Q4 2021

Feb 14, 2022

BUY
$3.23 - $4.6 $5.65 Million - $8.05 Million
1,750,000 New
1,750,000 $5.92 Million

Others Institutions Holding CBAY

About CymaBay Therapeutics, Inc.


  • Ticker CBAY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 84,677,904
  • Description
  • CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of pri...
More about CBAY
Track This Portfolio

Track Altium Capital Management LP Portfolio

Follow Altium Capital Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Altium Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Altium Capital Management LP with notifications on news.